Literature DB >> 24648958

Biochemical index and immunological function in the peripheral blood of patients with idiopathic pulmonary alveolar proteinosis.

Jiuwu Bai1, Huiping Li1, Jingyun Shi2, Jinfu Xu1, Xia Li1, Weijun Cao1, Haiqing Chu1, Jinming Liu1, Beilan Gao1.   

Abstract

Idiopathic pulmonary alveolar proteinosis (PAP) has recently been recognized as a disease of impaired alveolar macrophage function caused by the neutralizing granulocyte-macrophage colony stimulating factor (GM-CSF) autoantibody. However, the change of immunological function and biochemical index in the peripheral blood of patients with idiopathic PAP remains unclear. The clinical data of 29 patients with idiopathic PAP and 30 normal subjects were retrospectively analyzed. Biochemical indices, immunoglobulin and complement of all participants, and immunocytes in 19 patients and 30 normal subjects were evaluated. The peripheral blood of the patients showed a decrease in CD4+/CD8+ (P<0.05) and the percentage of the CD4+ T lymphocyte and helper T lymphocyte (both P<0.01), whereas an increase was observed in the percentage of the suppressor T lymphocyte (P<0.01) compared to the normal subjects. No significant differences were found in the concentration of IgG, IgA, IgM, C3 and C4 between the two groups. An increase was observed in LDH (P<0.01) and cytokeratin fragment antigen (CYFR) 211 (P<0.01) in the peripheral blood of the patients compared to that of normal subjects. The serum level of LDH was negatively correlated with FVC% Pred (P<0.05), DLCO% Pred (P<0.05), PaO2 (P<0.05) and positively associated with the dyspnea score (P<0.05) of 29 patients, and positively correlated with the score of high-resolution computed tomography (HRCT) of the chest of 21 patients (P<0.05). The serum level of CYFR211 was negatively correlated with DLCO% Pred (P<0.05) and positively associated with the dyspnea score (P<0.05). Findings of the present study suggest that hypofunction of cellular immunity may exist in the patients with idiopathic PAP. LDH and CYFRA211 may be considered as important indices to monitor the severity of idiopathic PAP.

Entities:  

Keywords:  cellular immunity; cytokeratin fragment antigen 211; idiopathic pulmonary alveolar proteinosis; lactate dehydrogenase

Year:  2013        PMID: 24648958      PMCID: PMC3917050          DOI: 10.3892/br.2013.66

Source DB:  PubMed          Journal:  Biomed Rep        ISSN: 2049-9434


  18 in total

1.  Pulmonary alveolar proteinosis: high-resolution CT, chest radiographic, and functional correlations.

Authors:  K N Lee; D L Levin; W R Webb; D Chen; M L Storto; J A Golden
Journal:  Chest       Date:  1997-04       Impact factor: 9.410

2.  Change in cytokeratin 19 fragment level according to the severity of pulmonary alveolar proteinosis.

Authors:  Y Minakata; Y Kida; H Nakanishi; T Nishimoto; S Yukawa
Journal:  Intern Med       Date:  2001-10       Impact factor: 1.271

3.  Pulmonary alveolar proteinosis: quantitative CT and pulmonary functional correlations.

Authors:  Yubao Guan; Qingsi Zeng; Haihong Yang; Jinping Zheng; Shiyue Li; Yi Gao; Yu Deng; Jiang Mei; Jianxing He; Nanshan Zhong
Journal:  Eur J Radiol       Date:  2011-05-28       Impact factor: 3.528

4.  Patient-derived granulocyte/macrophage colony-stimulating factor autoantibodies reproduce pulmonary alveolar proteinosis in nonhuman primates.

Authors:  Takuro Sakagami; David Beck; Kanji Uchida; Takuji Suzuki; Brenna C Carey; Koh Nakata; Gary Keller; Robert E Wood; Susan E Wert; Machiko Ikegami; Jeffrey A Whitsett; Maurizio Luisetti; Stella Davies; Jeffrey P Krischer; Alan Brody; Fred Ryckman; Bruce C Trapnell
Journal:  Am J Respir Crit Care Med       Date:  2010-03-11       Impact factor: 21.405

5.  BAL findings in a patient with pulmonary alveolar proteinosis successfully treated with GM-CSF.

Authors:  O D Schoch; U Schanz; M Koller; K Nakata; J F Seymour; E W Russi; A Boehler
Journal:  Thorax       Date:  2002-03       Impact factor: 9.139

6.  Exogenous granulocyte-macrophage colony-stimulating factor administration for pulmonary alveolar proteinosis.

Authors:  M S Kavuru; E J Sullivan; R Piccin; M J Thomassen; J K Stoller
Journal:  Am J Respir Crit Care Med       Date:  2000-04       Impact factor: 21.405

7.  High-affinity autoantibodies specifically eliminate granulocyte-macrophage colony-stimulating factor activity in the lungs of patients with idiopathic pulmonary alveolar proteinosis.

Authors:  Kanji Uchida; Koh Nakata; Bruce C Trapnell; Takahiro Terakawa; Emi Hamano; Ayako Mikami; Ikumi Matsushita; John F Seymour; Masayoshi Oh-Eda; Ikuo Ishige; Yoshinobu Eishi; Takayuki Kitamura; Yoshitsugu Yamada; Kazuo Hanaoka; Naoto Keicho
Journal:  Blood       Date:  2003-09-25       Impact factor: 22.113

8.  Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan.

Authors:  Yoshikazu Inoue; Bruce C Trapnell; Ryushi Tazawa; Toru Arai; Toshinori Takada; Nobuyuki Hizawa; Yasunori Kasahara; Koichiro Tatsumi; Masaaki Hojo; Toshio Ichiwata; Naohiko Tanaka; Etsuro Yamaguchi; Ryosuke Eda; Kazunori Oishi; Yoshiko Tsuchihashi; Chinatsu Kaneko; Toshihiro Nukiwa; Mitsunori Sakatani; Jeffrey P Krischer; Koh Nakata
Journal:  Am J Respir Crit Care Med       Date:  2008-01-17       Impact factor: 21.405

9.  Clinical significance of anti-GM-CSF antibodies in idiopathic pulmonary alveolar proteinosis.

Authors:  F-C Lin; G-D Chang; M-S Chern; Y-C Chen; S-C Chang
Journal:  Thorax       Date:  2006-03-03       Impact factor: 9.139

10.  Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor.

Authors:  T Kitamura; N Tanaka; J Watanabe; S Kanegasaki; Y Yamada; K Nakata
Journal:  J Exp Med       Date:  1999-09-20       Impact factor: 14.307

View more
  2 in total

1.  Longitudinal lung involvement of systemic lupus erythematosus-related vasculitis and alveolar proteinosis-like reaction.

Authors:  Takahito Suzuki; Noriyuki Enomoto; Yasuoki Horiike; Kazuhiro Asada; Toshihiro Shirai; Takafumi Suda
Journal:  Respirol Case Rep       Date:  2020-04-17

2.  CYFRA21-1 is a more sensitive biomarker to assess the severity of pulmonary alveolar proteinosis.

Authors:  Jiu-Wu Bai; Shui-Yi Gu; Xiao-Li Sun; Hai-Wen Lu; Shuo Liang; Jin-Fu Xu
Journal:  BMC Pulm Med       Date:  2022-01-03       Impact factor: 3.317

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.